Doravirin (J05AG06)

TENDER DESCRIPTION

The Kaufmännische Krankenkasse - KKH (hereinafter KKH) aims to conclude rebate contracts pursuant to § 130a paragraph 8 SGB V with all suitable pharmaceutical companies for the active ingredient named under BT-21-Lot (ATC) and possibly limited to certain dosage forms within the framework of a so-called "Open-House procedure." Under the provision of uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or associations of pharmaceutical companies are offered the conclusion or accession to a rebate contract pursuant to § 130a para. 8 SGB V for the aforementioned active ingredient. Interested pharmaceutical companies can request the participation documents and the contract from the mentioned contact address. A prerequisite for concluding a contract is that the interested pharmaceutical company submits the requested participation documents fully completed and signed. A contract will be concluded with each pharmaceutical company that meets the participation requirements. There is no exclusivity. Accession or contract conclusion can take place at any time and under the same conditions. Individual contract negotiations will…

TENDER BRIEF

TENDER DOCUMENTS